Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
← catalyst calendarSponsored by Cartesian Therapeutics (industry) · RNAC — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
30estimated
Sites
15
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-12-04 | actual | When the study began enrolling |
| Primary completion | 2026-01-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2019-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myasthenia Gravis, Generalized
Intervention
- Drug: Descartes-08
Primary outcome
what the primary-completion date above is the date OFProportion of patients with MG Composite improvement of ≥5 points.
measured Day 0 to Day 85
Publications
- PMID 41514039 — linked by the registry
- PMID 41514038 — linked by the registry
- PMID 37353278 — linked by the registry
- PMID 37353270 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RNAC's whole pipeline · Catalyst calendar · Every registered study · What changed